New cocktail aims to tackle tough myeloma cases
NCT ID NCT01242267
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a combination of thalidomide, bortezomib, and high-dose melphalan followed by a stem cell transplant in 29 patients with advanced multiple myeloma who had already failed one round of treatment. The goal was to find the safest dose of thalidomide and see how well the combo worked. Researchers measured side effects, response rates, and how long patients stayed in remission.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
thalidomide, bortezomib, melphalan, and stem cell transplant
What this could lead to
If successful, this combination could offer a new treatment option for patients with advanced multiple myeloma who have not responded to previous therapy.
What could go wrong
This is an early-phase trial with only 29 participants, so results may not apply broadly. The combination of drugs can cause significant side effects, and the study focuses on finding the safest dose rather than proving effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States